Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Checchi Capital Advisers LLC
Checchi Capital Advisers LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,222 shares of the life sciences company’s stock after purchasing an additional 40 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Illumina were worth $334,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in ILMN. Veracity Capital LLC grew its position in shares of Illumina by 37.3% during the first quarter. Veracity Capital LLC now owns 898 shares of the life sciences company’s stock worth $245,000 after acquiring an additional 244 shares during the last quarter. WASHINGTON TRUST Co purchased a new position in shares of Illumina during the first quarter worth approximately $4,781,000. First Trust Advisors LP grew its position in shares of Illumina by 3.2% during the first quarter. First Trust Advisors LP now owns 210,393 shares of the life sciences company’s stock worth $57,463,000 after acquiring an additional 6,562 shares during the last quarter. Rhumbline Advisers grew its position in shares of Illumina by 0.7% during the first quarter. Rhumbline Advisers now owns 266,098 shares of the life sciences company’s stock worth $72,677,000 after acquiring an additional 1,723 shares during the last quarter. Finally, Ashfield Capital Partners LLC grew its position in shares of Illumina by 0.3% during the first quarter. Ashfield Capital Partners LLC now owns 35,055 shares of the life sciences company’s stock worth $9,574,000 after acquiring an additional 115 shares during the last quarter. 92.26% of the stock is currently owned by institutional investors.
A number of equities analysts have recently issued reports on the stock. Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and raised their target price for the stock from $250.00 to $320.00 in a research report on Friday, April 24th. They noted that the move was a valuation call. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Barclays lowered their price objective on shares of Illumina from $390.00 to $350.00 and set an “overweight” rating on the stock in a research report on Thursday, March 26th. Zacks Investment Research lowered shares of Illumina from a “hold” rating to a “sell” rating and set a $341.00 price objective on the stock. in a research report on Monday, January 20th. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $340.00 price objective on shares of Illumina in a research report on Tuesday, February 4th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $329.88.
Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.64 EPS for the quarter, topping the consensus estimate of $1.25 by $0.39. The company had revenue of $859.00 million for the quarter, compared to analyst estimates of $857.92 million. Illumina had a net margin of 26.48% and a return on equity of 21.78%. The business’s revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.60 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 6.25 earnings per share for the current fiscal year.
In other news, SVP Aimee L. Hoyt sold 417 shares of Illumina stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $273.95, for a total transaction of $114,237.15. Following the completion of the transaction, the senior vice president now owns 3,689 shares of the company’s stock, valued at approximately $1,010,601.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Charles Dadswell sold 121 shares of Illumina stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $265.92, for a total value of $32,176.32. Following the transaction, the senior vice president now directly owns 9,962 shares of the company’s stock, valued at approximately $2,649,095.04. The disclosure for this sale can be found here. Insiders have sold a total of 23,741 shares of company stock worth $7,152,324 over the last 90 days. Insiders own 0.38% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: Are FAANG stocks a good investment?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.